{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:12:22Z","timestamp":1786990342204,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.iac.2024.07.004","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T17:38:35Z","timestamp":1724348315000},"page":"645-655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Biologics in Food Allergies"],"prefix":"10.1016","volume":"44","author":[{"given":"Michele","family":"Beaudoin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Citron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwaljit K.","family":"Brar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.iac.2024.07.004_bib1","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-1235","article-title":"The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States","volume":"142","author":"Gupta","year":"2018","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.iac.2024.07.004_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.5630","article-title":"Prevalence and Severity of Food Allergies Among US Adults","volume":"2","author":"Gupta","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.iac.2024.07.004_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40521-022-00314-5","article-title":"Accidental Reactions to Foods: Frequency, Causes, and Severity","volume":"9","author":"Rotella","year":"2022","journal-title":"Curr Treat Options Allergy"},{"issue":"1","key":"10.1016\/j.iac.2024.07.004_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12016-018-8708-x","article-title":"Beyond Avoidance: the Psychosocial Impact of Food Allergies","volume":"57","author":"Feng","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.iac.2024.07.004_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2023.1060932","article-title":"Food allergy risks and dining industry - an assessment and a path forward","volume":"4","author":"Stankovich","year":"2023","journal-title":"Front Allergy"},{"issue":"3","key":"10.1016\/j.iac.2024.07.004_bib6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/eji.202048833","article-title":"IgE in the pathophysiology and therapy of food allergy","volume":"51","author":"Michelet","year":"2021","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.iac.2024.07.004_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.anai.2023.01.029","article-title":"Jak out of the box: Targeting Bruton's tyrosine kinase, sialic acid-binding immunoglobulin-like lectin-8, and Janus kinase 1 in food allergy","volume":"131","author":"Berin","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"10.1016\/j.iac.2024.07.004_bib8","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMoa022613","article-title":"Effect of anti-IgE therapy in patients with peanut allergy","volume":"348","author":"Leung","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.iac.2024.07.004_bib9","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2011.01.051","article-title":"A\u00a0phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy","volume":"127","author":"Sampson","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2024.07.004_bib10","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaci.2012.05.039","article-title":"Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy","volume":"130","author":"Savage","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2024.07.004_bib11","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cea.12862","article-title":"Individually dosed omalizumab: an effective treatment for severe peanut allergy","volume":"47","author":"Brandstr\u00f6m","year":"2017","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.iac.2024.07.004_bib12","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaci.2013.09.046","article-title":"A\u00a0pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients","volume":"132","author":"Schneider","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2024.07.004_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacig.2022.05.006","article-title":"Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)","volume":"1","author":"Wood","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Glob."},{"issue":"3","key":"10.1016\/j.iac.2024.07.004_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaci.2004.11.053","article-title":"The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation","volume":"115","author":"Holgate","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.iac.2024.07.004_bib15","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","article-title":"Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects","volume":"44","author":"Arm","year":"2014","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.iac.2024.07.004_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.anai.2023.03.030","article-title":"Anti-immunoglobulin E for food allergy","volume":"131","author":"Dantzer","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"10.1016\/j.iac.2024.07.004_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100690","article-title":"The rationale for development of ligelizumab in food allergy","volume":"15","author":"Wood","year":"2022","journal-title":"World Allergy Organ J"},{"issue":"10422","key":"10.1016\/j.iac.2024.07.004_bib18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(23)01684-7","article-title":"Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials","volume":"403","author":"Maurer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2024.07.004_bib19","unstructured":"Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy, Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT04984876. (Accessed March 2 2024). 2023."},{"key":"10.1016\/j.iac.2024.07.004_bib20","unstructured":"Long-term Extension Study of Ligelizumab in Food Allergy, Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05678959. (Accessed April 15 2024). 2023."},{"issue":"10","key":"10.1016\/j.iac.2024.07.004_bib21","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the Treatment of Multiple Food Allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.iac.2024.07.004_bib22","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jaip.2022.11.036","article-title":"Omalizumab in IgE-Mediated Food Allergy: A Systematic Review and Meta-Analysis","volume":"11","author":"Zuberbier","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2024.07.004_bib23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaip.2018.09.015","article-title":"Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab","volume":"7","author":"Yee","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2024.07.004_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1710-1492-10-7","article-title":"Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab","volume":"10","author":"B\u00e9gin","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2024.07.004_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.iac.2024.07.004_bib26","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2024.07.004_bib27","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jaip.2019.01.023","article-title":"Impact of Omalizumab on Food Allergy in Patients Treated for Asthma: A Real-Life Study","volume":"7","author":"Fiocchi","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.iac.2024.07.004_bib28","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.jaci.2009.09.042","article-title":"Adverse reactions during peanut oral immunotherapy home dosing","volume":"124","author":"Varshney","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2024.07.004_bib29","first-page":"1","article-title":"Food allergy among U.S. children: trends in prevalence and hospitalizations","author":"Branum","year":"2008","journal-title":"NCHS Data Brief"},{"issue":"1","key":"10.1016\/j.iac.2024.07.004_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of Dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.iac.2024.07.004_bib31","unstructured":"Study to evaluate dupilumab monotherapy in pediatric patients with peanut allergy, Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03793608. (Accessed March 2 2024). 2022."},{"key":"10.1016\/j.iac.2024.07.004_bib32","unstructured":"Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy), Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT03682770. (Accessed March 2 2024). 2024."},{"key":"10.1016\/j.iac.2024.07.004_bib33","unstructured":"Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE), Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT03679676. (Accessed March 2 2024). 2023."},{"issue":"7","key":"10.1016\/j.iac.2024.07.004_bib34","first-page":"2699","article-title":"Emerging Role of Alarmins in Food Allergy: An Update on Pathophysiological Insights, Potential Use as Disease Biomarkers, and Therapeutic Implications","volume":"12","author":"Rizzi","year":"2023","journal-title":"J\u00a0Clin Med"},{"issue":"22","key":"10.1016\/j.iac.2024.07.004_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131347","article-title":"Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy","volume":"4","author":"Chinthrajah","year":"2019","journal-title":"JCI Insight"},{"issue":"16","key":"10.1016\/j.iac.2024.07.004_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172335","article-title":"A\u00a0phase II study of Bruton's tyrosine kinase inhibition for the prevention of anaphylaxis","volume":"133","author":"Suresh","year":"2023","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.iac.2024.07.004_bib37","unstructured":"JAK Inhibition in Food Allergy, Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT05069831. (Accessed March 2 2024). 2024."}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856124000535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T08:39:37Z","timestamp":1728376777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856124000535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0889856124000535"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2024.07.004","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics in Food Allergies","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2024.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}